Perspective Therapeutics (CATX) Asset Writedowns and Impairment (2016 - 2025)

Perspective Therapeutics has disclosed Asset Writedowns and Impairment across 5 years of filings, most recently posting $10.0 million for Q4 2025.

• Asset Writedowns and Impairment for Q4 2025 came in at $10.0 million, up 17141.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.3 million (up 1627.85% YoY), and the FY2025 annual result was $10.0 million, changed N/A from the prior year.
• Asset Writedowns and Impairment came in at $10.0 million for Q4 2025 at Perspective Therapeutics, up from $58000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $10.0 million in Q4 2025 to a low of -$58000.0 in Q3 2024.
• The 3-year median for Asset Writedowns and Impairment is $298000.0 (2023), against an average of $2.1 million.
• Across the five-year window, Asset Writedowns and Impairment sank 119.46% in 2024 and jumped 17141.38% in 2025, its largest moves.
• Perspective Therapeutics' Asset Writedowns and Impairment stood at $298000.0 in 2023, then tumbled by 80.54% to $58000.0 in 2024, then surged by 17141.38% to $10.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $10.0 million (Q4 2025), $58000.0 (Q4 2024), and -$58000.0 (Q3 2024), per Business Quant data.